Wolfgang Hueber

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky et al. · Gut · 2012 · 1.5K citations · Full text

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus P. Dryja et al. · Science Translational Medicine · 2010 · 858 citations

Autoantigen microarrays for multiplex characterization of autoantibody responses

William H. Robinson, Carla DiGennaro, Wolfgang Hueber et al. · Nature Medicine · 2002 · 676 citations

Autoantigen Microarrays, Functional Genomics, Engineering +7

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Dominique Baeten, Xenofon Baraliakos, Jürgen Braun et al. · The Lancet · 2013 · 585 citations

Inflammation, Rheumatology, Rheumatoid Disorder +12

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Iain B. McInnes, Joachim Sieper, Jürgen Braun et al. · Annals of the Rheumatic Diseases · 2013 · 339 citations